Ultrasound-guided versus conventional lung recruitment manoeuvres in thoracic surgery: A randomised controlled study

Abstract Purpose: Although lung recruitment manoeuvres (RMs) during mechanical ventilation may reduce atelectasis, the optimal recruitment strategy for patients undergoing thoracic surgery remains unknown. Our study was to investigate whether ultrasound-guided lung RMs is superior to conventional RMs in reducing incidence of perioperative atelectasis during thoracic surgery with one-lung ventilation. Methods: We conducted a randomised controlled trial from August 2022 to September 2022. Sixty patients scheduled for video-assisted thoracoscopic surgery (VATS) under general anaesthesia were enrolled. Subjects were randomly divided into the ultrasound-guided RMs group (manual inflation guided by lung ultrasound) or conventional RMs group (manual inflation with 30 cmH2O pressure). Ultrasound were performed at three predefined time points (1 min after anaesthetic induction; after RMs at the end of surgery; before discharge from postanesthesia care unit [PACU]). The primary outcome was lung ultrasound score before discharge from the PACU after extubation. Results: In the early postoperative period, lung aeration deteriorated in both groups even after lung RMs. However, ultrasound-guided lung RMs had significantly lower lung ultrasound scores when compared with conventional RMs in bilateral lungs (2.0 [0.8–4.0] vs. 8.0 [3.8–10.3], P < 0.01) at the end of surgery, which remained before patients discharged from the PACU. Accordingly, the lower incidence of atelectasis was found in ultrasound-guided RMs group than in conventional RMs group (7% vs. 53%; P < 0.01) at the end of surgery. Conclusion: Ultrasound-guided RMs is superior to conventional RMs in improving lung aeration and reducing lung atelectasis at early postoperative period in patients undergoing VATS. Trial registration: The study protocol was approved by the Institutional Review Board of the Fudan University Shanghai Cancer Center (No.220825810; date of approval: August 5, 2022) and registered on Chinese Clinical Trial Registry (number: ChiCTR2200062761).